caa a22 4500 469120711 CHVBK 20180323133138.0 cr unu---uuuuu 170328e19920601xx s 000 0 eng 10.1007/BF02245134 doi (NATIONALLICENCE)springer-10.1007/BF02245134 A placebo controlled trial of remoxipride in the prevention of relapse in chronic schizophrenia [Elektronische Daten] [D. King, M. Blomqvist, S. Cooper, M. Doherty, M. Mitchell, R. Montgomery] Sixty-two DSM III chronic schizophrenic inpatients were selected for a double-blind, placebo controlled, multi-centre, relapse prevention study of remoxipride, a selective dopamine (D2)-receptor antagonist. After a 1 month placebo washout, 23 patients had relapsed and were withdrawn. Of the remaining patients 19 were randomised to remoxipride (150-300 mg daily) and 20 to placebo. Their median age was 58 years, 26 were male, and the median duration of illness was 33 years. After 24 weeks a further total of 8 remoxipride and 17 placebo patients had been withdrawn. Excluding three patients withdrawn for reasons other than relapse, the comparative relapse rates were 37% and 75%, respectively (P=0.015). Efficacy analyses using clinical global impression (P=0.04) and change in BPRS scores (P=0.016) were in favour of remoxipride. Extrapyramidal symptoms were minimal in both groups. Treatment emergent adverse events were similar in the two groups. Remoxipride is therefore of potential value as a safe drug which is both effective and well tolerated in the long term management of chronic schizophrenic patients. Springer-Verlag, 1992 Remoxipride nationallicence Neuroleptics nationallicence Placebo controlled trial nationallicence Chronic schizophrenia nationallicence Relapse rates nationallicence Relapse prevention nationallicence King D. Department of Therapeutics and Pharmacology, The Queen's University of Belfast, Whitla Medical Building, 97 Lisburn Road, BT9 7BL, Belfast, Northern Ireland aut Blomqvist M. Astra Research Centre AB, S-15185, Södertälje, Sweden aut Cooper S. Department of Mental Health, The Queen's University of Belfast, Whitla Medical Building, 97 Lisburn Road, BT9 7BL, Belfast, Northern Ireland aut Doherty M. Purdysburn Hospital, Saintfield Road, BT8 8BH, Belfast, Northern Ireland aut Mitchell M. Astra Clinical Research Unit, 10 York Place, EH1 3EP, Edinburgh, UK aut Montgomery R. Astra Clinical Research Fellow, Holywell Hospital, Steeple Road, BT41 2RJ, Antrim, Northern Ireland aut Psychopharmacology Springer-Verlag 107/2-3(1992-06-01), 175-179 0033-3158 107:2-3<175 1992 107 213 https://doi.org/10.1007/BF02245134 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF02245134 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- King D. Department of Therapeutics and Pharmacology, The Queen's University of Belfast, Whitla Medical Building, 97 Lisburn Road, BT9 7BL, Belfast, Northern Ireland aut NATIONALLICENCE 700 1- Blomqvist M. Astra Research Centre AB, S-15185, Södertälje, Sweden aut NATIONALLICENCE 700 1- Cooper S. Department of Mental Health, The Queen's University of Belfast, Whitla Medical Building, 97 Lisburn Road, BT9 7BL, Belfast, Northern Ireland aut NATIONALLICENCE 700 1- Doherty M. Purdysburn Hospital, Saintfield Road, BT8 8BH, Belfast, Northern Ireland aut NATIONALLICENCE 700 1- Mitchell M. Astra Clinical Research Unit, 10 York Place, EH1 3EP, Edinburgh, UK aut NATIONALLICENCE 700 1- Montgomery R. Astra Clinical Research Fellow, Holywell Hospital, Steeple Road, BT41 2RJ, Antrim, Northern Ireland aut NATIONALLICENCE 773 0- Psychopharmacology Springer-Verlag 107/2-3(1992-06-01), 175-179 0033-3158 107:2-3<175 1992 107 213 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer